Mode
Text Size
Log in / Sign up
N/A Completed N=17 Randomized Quadruple-blind Treatment

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

Source: ClinicalTrials.gov NCT00467818 ↗
Enrolled (actual)
17
Serious AEs
5.9%
Results posted
Dec 2020
Primary outcomePrimary: Clinical Global Impression Scale(CGI)- Improvement — 3.57; 3.8 units on a scale — p=1.0

Summary

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: * Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. * Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. * Omega 3 fatty acids will be superior to placebo in improving functional ability.

Outcome Measures

OutcomeResultp-value
PRIMARY
Clinical Global Impression Scale(CGI)- Improvement
3.57; 3.8 1.0
PRIMARY
Aberrant Behavior Checklist (ABC)
5.66; 8.5 0.10
PRIMARY
Vineland Adaptive Behavior Scale
51.5; 27.5
SECONDARY
Overt Aggression Scale-Modified
3.8; 2.4 <0.5
SECONDARY
Parental Stress Index
314.2; 279.5 0.5

Eligibility Criteria

Inclusion Criteria

  • Child/Teen has autism.
  • He/She is between five and seventeen years of age.
  • He/She is not in the hospital.
  • He/She has a parent or legal guardian who is willing and able to sign the informed consent.

Exclusion Criteria

  • Child/Teen has been diagnosed with a psychotic disorder (such as schizophrenia) or a mood disorder, including depression or bipolar disorder (manic depression).
  • He/She has caused visible harm to him/herself or is at risk for suicide.
  • He/She has an active seizure disorder or epilepsy (seizures within the past year).
  • He/She has an unstable medical illness, including heart disease.
  • He/She has experienced brain injury.
  • He/She has a history of diabetes.
  • He/She has a history of prior treatment with Omega 3 Fatty Acids.
  • He/She lives in a far away area and/or does not have regular access to transportation to the clinical facility.
  • A pregnant female or unwilling to use acceptable contraception if sexually active.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00467818). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search